Literature DB >> 28572126

Shortened multidrug-resistant tuberculosis regimens overcome low-level fluoroquinolone resistance.

Armand Van Deun1,2, Chen-Yuan Chiang3,4,5.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28572126     DOI: 10.1183/13993003.00223-2017

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


× No keyword cloud information.
  6 in total

1.  Treatment of Drug-Resistant Tuberculosis. An Official ATS/CDC/ERS/IDSA Clinical Practice Guideline.

Authors:  Payam Nahid; Sundari R Mase; Giovanni Battista Migliori; Giovanni Sotgiu; Graham H Bothamley; Jan L Brozek; Adithya Cattamanchi; J Peter Cegielski; Lisa Chen; Charles L Daley; Tracy L Dalton; Raquel Duarte; Federica Fregonese; C Robert Horsburgh; Faiz Ahmad Khan; Fayez Kheir; Zhiyi Lan; Alfred Lardizabal; Michael Lauzardo; Joan M Mangan; Suzanne M Marks; Lindsay McKenna; Dick Menzies; Carole D Mitnick; Diana M Nilsen; Farah Parvez; Charles A Peloquin; Ann Raftery; H Simon Schaaf; Neha S Shah; Jeffrey R Starke; John W Wilson; Jonathan M Wortham; Terence Chorba; Barbara Seaworth
Journal:  Am J Respir Crit Care Med       Date:  2019-11-15       Impact factor: 21.405

2.  A Highly Sensitive and Specific Detection Method for Mycobacterium tuberculosis Fluoroquinolone Resistance Mutations Utilizing the CRISPR-Cas13a System.

Authors:  Xiaopeng Bai; Panqi Gao; Keli Qian; Jiandong Yang; Haijun Deng; Tiwei Fu; Yuan Hu; Miaomiao Han; Huizhi Zheng; Xiaoxia Cao; Yuliang Liu; Yaoqin Lu; Ailong Huang; Quanxin Long
Journal:  Front Microbiol       Date:  2022-05-13       Impact factor: 6.064

3.  Genetic characterization of Mycobacterium tuberculosis complex isolates circulating in Abuja, Nigeria.

Authors:  Barbara Molina-Moya; Saddiq T Abdurrahman; Laura I Madukaji; Michel Kiréopori Gomgnimbou; Lizania Spinasse; Meissiner Gomes-Fernandes; Harrison Magdinier Gomes; Sarah Kacimi; Russell Dacombe; John S Bimba; Lovett Lawson; Christophe Sola; Luis E Cuevas; Jose Dominguez
Journal:  Infect Drug Resist       Date:  2018-10-01       Impact factor: 4.003

4.  Exploration of Synergistic Action of Cell Wall-Degrading Enzymes against Mycobacterium tuberculosis.

Authors:  Loes van Schie; Katlyn Borgers; Gitte Michielsen; Evelyn Plets; Marnik Vuylsteke; Petra Tiels; Nele Festjens; Nico Callewaert
Journal:  Antimicrob Agents Chemother       Date:  2021-07-19       Impact factor: 5.191

5.  Treatment outcomes of patients with MDR-TB in Nepal on a current programmatic standardised regimen: retrospective single-centre study.

Authors:  Samiksha Ghimire; Samriddhi Karki; Bhagwan Maharjan; Jos G W Kosterink; Daan J Touw; Tjip S van der Werf; Bhabana Shrestha; Jan-Willem Alffenaar
Journal:  BMJ Open Respir Res       Date:  2020-08

6.  Bedaquiline can act as core drug in a standardised treatment regimen for fluoroquinolone-resistant rifampicin-resistant tuberculosis.

Authors:  Tom Decroo; Kya Jai Maug Aung; Mohamed Anwar Hossain; Mourad Gumusboga; Nimer Ortuno-Gutierrez; Bouke Catherine De Jong; Armand Van Deun
Journal:  Eur Respir J       Date:  2022-03-24       Impact factor: 16.671

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.